malattie cardiache congenite

I vantaggi della correzione mininvasiva delle cardiopatie congenite riletti dopo 25 anni di esperienza

Cattapan C, Guariento A, Castaldi B, Sirico D, Scattolin F, Padalino M, Di Salvo G, Vida V

2023/9 — pag. 167-176 — DOI

Background - For many years the treatment of congenital heart disease has been performed through median sternotomy. Recently, the dimensions of the cutaneous incision have been reduced to optimize functional recovery and improve the aesthetic result....

La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab

Servadio M, Belleudi V, Marchetti F, Addis A.

2022/10 — pag. 632-639 — DOI

The Respiratory Syncytial Virus (RSV) is considered the leading cause of lower respiratory tract infections (LRTI) in children aged < 2 years. In high-risk children, including preterm infants, or in children with bronchopulmonary dysplasia (BPD) and ...

L’adolescente e il giovane adulto con cardiopatia congenita

A. Benettoni, J. Somerville

2003/4 — pag. 243-249

The article addresses the needs and problems of grown-up congenital heart (GUCH) patients. The size of GUCH population is uncertain, but since 80-85% of patients born with congenital heart disease (CHD) now survive to adulthood (age 16 years), an a...

Profilassi dell'endocardite batterica: nuove linee guida

1999/3